NantHealth (NASDAQ:NH) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a note issued to investors on Tuesday.
According to Zacks, “Nant Health, LLC is a personalized healthcare company which enable improved patient outcomes and treatment decisions for critical illnesses. The company developed an adaptive learning system, CLINICS, which includes its unique software, middleware and hardware systems infrastructure that collects, indexes, analyzes and interprets of molecular, clinical, operational and financial data points derived from novel and traditional sources. Nant Health, LLC is based in CULVER CITY, United States. “
A number of other equities analysts also recently commented on the company. BidaskClub downgraded NantHealth from a “sell” rating to a “strong sell” rating in a report on Wednesday, December 6th. Canaccord Genuity decreased their target price on NantHealth from $6.00 to $5.00 and set a “buy” rating for the company in a report on Friday, November 17th. Finally, Jefferies Group restated a “buy” rating and set a $5.00 target price on shares of NantHealth in a report on Thursday, September 28th. One analyst has rated the stock with a sell rating and five have assigned a buy rating to the company. NantHealth presently has a consensus rating of “Buy” and a consensus price target of $8.05.
NantHealth (NASDAQ:NH) last announced its earnings results on Thursday, November 9th. The company reported ($0.13) EPS for the quarter, beating analysts’ consensus estimates of ($0.14) by $0.01. The company had revenue of $21.76 million during the quarter, compared to the consensus estimate of $29.42 million. NantHealth had a negative return on equity of 46.09% and a negative net margin of 225.76%. The firm’s revenue for the quarter was up 5.3% on a year-over-year basis. During the same quarter in the prior year, the company earned ($0.18) earnings per share. equities analysts predict that NantHealth will post -1.35 EPS for the current year.
A number of institutional investors and hedge funds have recently bought and sold shares of NH. Dimensional Fund Advisors LP bought a new position in NantHealth in the third quarter worth $365,000. Northern Trust Corp raised its holdings in NantHealth by 133.9% in the second quarter. Northern Trust Corp now owns 151,907 shares of the company’s stock worth $643,000 after purchasing an additional 86,955 shares in the last quarter. Goldman Sachs Group Inc. raised its holdings in NantHealth by 91.5% in the second quarter. Goldman Sachs Group Inc. now owns 169,603 shares of the company’s stock worth $717,000 after purchasing an additional 81,024 shares in the last quarter. Vanguard Group Inc. raised its holdings in NantHealth by 20.2% in the second quarter. Vanguard Group Inc. now owns 423,537 shares of the company’s stock worth $1,792,000 after purchasing an additional 71,087 shares in the last quarter. Finally, State Street Corp raised its holdings in NantHealth by 88.1% in the second quarter. State Street Corp now owns 147,234 shares of the company’s stock worth $623,000 after purchasing an additional 68,963 shares in the last quarter. Institutional investors and hedge funds own 7.10% of the company’s stock.
COPYRIGHT VIOLATION WARNING: “NantHealth (NH) Cut to Hold at Zacks Investment Research” was originally published by Markets Daily and is the property of of Markets Daily. If you are viewing this piece on another publication, it was stolen and republished in violation of international copyright and trademark law. The original version of this piece can be viewed at https://www.themarketsdaily.com/2018/01/13/nanthealth-nh-cut-to-hold-at-zacks-investment-research.html.
NantHealth Company Profile
NantHealth, Inc is a healthcare cloud-based information technology (IT) company. The Company is engaged in converging science and technology through a single integrated clinical platform, to provide actionable health information at the point of care. The Company offers the Genomic Proteomic Spectrometry (GPS) Cancer test, a molecular test and decision support solution that measures the proteins present in the patient’s tumor tissue, combined with whole genomic and transcriptomic sequencing of tumor and normal samples.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for NantHealth Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NantHealth and related companies with MarketBeat.com's FREE daily email newsletter.